"Advancing obesity and obesity-related trials with patients at the center of development.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLES
Our methodology and relationship with sites ensure the most comprehensive dataset are generated to meet evidence needs for all audiences. From internal stakeholders to HCPs, to regulatory or market access agencies, across the whole lifecycle of a product.
Natural history of diseases studies provides essential insights into disease progression, patient populations, and long-term outcomes. These insights can be used for dissemination to the scientific community, to inform clinical trial design and to complement regulatory and market access submissions.
Selected case studies
| Attrition rates from first- to third-line therapy in HER2+ metastatic breast cancer in Europe | Real-world analysis of epithelial ovarian cancer treatment and outcomes | Treatment patterns and outcomes in lenalidomide-exposed multiple myeloma patients | Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer |
External comparators enable to benchmark the effectiveness of a new treatment against existing therapies, either to fulfil regulatory requirements, market access and reimbursement decisions, or to support decision-making by investors. They can provide essential data on real-world effectiveness and safety, helping to identify patient populations and understand long-term outcomes.
Selected case studies
| Outcomes in patients with relapsed/refractory DLBCL treated with systemic therapy | Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma | Efficacy comparison with standard of care in adults with advanced NSCLC with activating EGFR exon20ins | Comparison of idecabtagene vicleucel with real world outcomes in relapsed and refractory multiple myeloma |
Evidence Platforms leverage a network of sites to provide deep and longitudinal insights into clinical practices and outcomes. They can address wide evidence needs, from strategy planning to scientific dissemination, and be used to provide competitive advantage, enhance stakeholder engagement or guide product development and marketing activities.
Selected publications from the I-O Optimise Evidence Platform:
| Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer | Real-world outcomes in patients with resected non-small cell lung cancer receiving (neo)adjuvant treatment in Germany | Treatment patterns and survival outcomes for advanced non-small cell lung cancer in the preimmunotherapy era in Portugal | Real-world outcomes in nonmetastatic non-small cell lung cancer |
Testing archived samples collected during the patient care journey for retrospective biomarker identification can be highly valuable for understanding outcomes and treatment patterns of biomarker-defined populations when investigating a new biomarker or a new mutational variant.
Selected case studies
| Leveraging real world evidence to support oncology targeted therapies | Treatment patterns in ESR1 mutated patients with metastatic breast cancer |
HEOR studies evaluate the cost-effectiveness and real-world performance of new therapies. The results of these studies can be used to support reimbursement and pricing discussions.
Speak to us to find out how we can support your HTA dossier submission through a HEOR study
